Edwards Lifesciences Shares New Data on Mitral and Tricuspid Therapies
Edwards Lifesciences (NYSE: EW) has shared new data demonstrating successful outcomes with its mitral and tricuspid therapies, including the Evoque and Sapien M3 valves, at the 2025 Transcatheter Cardiovascular Therapeutics (TCT) conference in San Francisco.
- The company presented one-year data from the ENCIRCLE single-arm pivotal trial.
- 30-day data from the EVOQUE STS/ACC TVT registry was also shared.
The ENCIRCLE trial achieved all primary and secondary endpoints for safety and effectiveness, with data published in The Lancet. Additionally, the EVOQUE valve outperformed results from the company's previous TRISCEND II pivotal trial for the tricuspid valve.
Author's summary: Edwards Lifesciences shares new data on successful mitral and tricuspid therapies.
More News
- Orban seeks Trump’s support over reliance on Russian energy amid US sanctions
- Dallas Mavericks Look to Rebound From Slow Start Amid Offensive Struggles
- WATCH LIVE: Trump meets with Hungary's Prime Minister Viktor Orbán
- Jack Osbourne and Kelly Brook among stars ‘set to join I’m a Celebrity 2025’
- Kelly Brook in I’m A Celeb 2025: Was she engaged to Jason Statham and Billy Zane
- Poppy waterfall unveiled as part of Shropshire village's major remembrance tribute
- Maple Leafs F Kampf away from team pondering future after AHL demotion
- Ireland suffering from 'reverse poppy facism' - Ciara Kelly
- Dodgers favored to sign $427M superstar free agent after World Series win
- Prince Harry apologises to Canada for wearing LA Dodgers hat at World Series game: ‘Was under duress’ | Mint